Related Experiment Video
Updated: Dec 15, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Evaluation of Complications in Postpartum Women Receiving Therapeutic Anticoagulation
Gabrielle Côté-Poirier1, Nazila Bettache, Anne-Marie Côté
1Division of Internal Medicine, Hôpital de Lasalle, CIUSSS de l'Ouest-de-l'Île, the Division of Internal and Obstetric Medicine, Centre Hospitalier de l'Université de Montréal, the Centre de Recherche Université de Montréal, and the Division of Obstetric Medicine, CHU-Sainte-Justine, Université de Montréal, Montréal, and the Division of Nephrology and Obstetric Medicine, CIUSSS de l'Estrie-CHUS, the Division of Obstetric Medicine, CIUSSS de l'Estrie-CHUS, the Department of Obstetrics & Gynecology, CIUSSS de l'Estrie-CHUS, the Department of Medicine, CIUSSS de l'Estrie-CHUS, Research Professional, and the Division of Internal and Obstetric Medicine, CIUSSS de l'Estrie-CHUS, University of Sherbrooke, Sherbrooke, Québec, Canada.
Objective:
To evaluate complications associated with early postpartum therapeutic anticoagulation.
Methods:
A multicenter retrospective cohort study was done to evaluate the association between therapeutic anticoagulation postpartum and major complications (hemorrhagic and wound complications). Secondary outcomes included minor complications, risk factors associated with total complications (including the time to therapeutic anticoagulation resumption after delivery) and recurrent thrombotic events within 6 weeks postpartum.
Results:
From 2003 to 2015, 232 consecutive women were treated with therapeutic anticoagulation within 96 hours postpartum; among those treated, 91 received unfractionated heparin, 138 received low-molecular-weight heparin, and three received other anticoagulants. The primary outcome, a composite of major hemorrhagic complications (requiring transfusion, hospitalization, volume resuscitation, transfer to intensive care unit, or surgery) and major wound complications, occurred in 7 of 83 (8.4%) for cesarean deliveries and 9 of 149 (6.0%) for vaginal deliveries (P=.490). Total complications (including major and minor hemorrhagic and wound complications) occurred in 13 of 83 (15.7%) for cesarean deliveries compared with 9 of 149 (6.0%) for vaginal deliveries (P=.016). When comparing cases associated with and without complications, the median delay before resuming anticoagulation was significantly shorter for both cesarean (12 vs 33 hours, P=.033) and vaginal deliveries (6 vs 19 hours, P=.006). For vaginal deliveries, 8 of 51 (15.7%) women had complications when anticoagulation was started before 9.25 hours postpartum, compared with 1 of 98 (1.0%) when started after 9.25 hours. For cesarean deliveries, 7 of 21 (33.3%) of women experienced complications compared with 6 of 62 (9.7%) if anticoagulation was started before or after 15.1 hours, respectively. Two (0.9%) episodes of venous thromboembolism occurred within 6 weeks postpartum.
Conclusion:
Among postpartum women who received early therapeutic anticoagulation, major complications occurred in 8.4% for cesarean deliveries and 6.0% for vaginal deliveries. Complications were associated with earlier resumption of therapeutic anticoagulation, particularly before 9.25 hours for vaginal deliveries and before 15.1 hours for cesarean deliveries.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease V: Postoperative Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

